Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -116.28% is 149% below its 5-year average of -46.66%, near the low end of its 5-year range (-158.26%–-0.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 29.54% below its 12-month average of -89.76%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -116.28%.
RETURN ON EQUITY (ROE)
-116.28%
RETURN ON EQUITY (ROE) AVG TTM
-89.76%
RETURN ON EQUITY (ROE) AVG 3Y
-69.53%
RETURN ON EQUITY (ROE) AVG 5Y
-46.66%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.54%
CURRENT VS 3Y AVG
-67.22%
CURRENT VS 5Y AVG
-149.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.44%
median of 550 covered companies
CURRENT VS SECTOR MEDIAN
-194.86%
vs the sector median at left
Definitive Healthcare Corp.
Market Cap
$105.48M
Return on Equity (ROE)
-116.28%
TTM Avg
-89.76%
3Y Avg
-69.53%
5Y Avg
-46.66%
Market Cap
$107.28M
Return on Equity (ROE)
-60.82%
TTM Avg
-19.88%
3Y Avg
-19.08%
5Y Avg
-15.27%
Market Cap
$107.44M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
Market Cap
$107.75M
Return on Equity (ROE)
-87.45%
TTM Avg
455.42%
3Y Avg
120.34%
5Y Avg
63.42%
Market Cap
$108.29M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$108.64M
Return on Equity (ROE)
-80.97%
TTM Avg
-121.11%
3Y Avg
-93.50%
5Y Avg
-70.15%
Market Cap
$101.93M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$101.65M
Return on Equity (ROE)
-34.11%
TTM Avg
-78.33%
3Y Avg
-16.94%
5Y Avg
-8.09%
Market Cap
$109.42M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definitive Healthcare Corp. (DH) | $105.48M | -116.28% | -89.76% | -69.53% | -46.66% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | -60.82% | -19.88% | -19.08% | -15.27% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | -44.29% | -31.86% | -53.29% | -49.85% |
| Immunic, Inc. (IMUX)vs › | $107.75M | -87.45% | 455.42% | 120.34% | 63.42% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.29M | -99.67% | -40.73% | 98.81% | 13.93% |
| Apyx Medical Corporation (APYX)vs › | $108.64M | -80.97% | -121.11% | -93.50% | -70.15% |
| The Joint Corp. (JYNT)vs › | $101.93M | 23.96% | -4.38% | -11.56% | 6.84% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $101.65M | -34.11% | -78.33% | -16.94% | -8.09% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.42M | -93.44% | -8.16% | 13.24% | 13.24% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | N/A | 148.53% | -12.61% | -408.56% |
ROE
-116.3%
ROA
-33.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -116.28% |
| 2026-03-31 | -116.47% |
| 2025-12-31 | -49.42% |
| 2025-09-30 | -66.24% |
| 2025-06-30 | -100.37% |
| 2025-03-31 | -158.26% |
| 2024-12-31 | -92.97% |
| 2024-09-30 | -71.92% |
| 2024-06-30 | -62.80% |
| 2024-03-31 | -23.23% |
| 2023-12-31 | -23.50% |
| 2023-09-30 | -21.12% |
| 2023-06-30 | -1.37% |
| 2023-03-31 | -1.08% |
| 2022-12-31 | -0.76% |
| 2022-09-30 | -2.97% |
| 2022-06-30 | -4.49% |
| 2022-03-31 | -5.72% |
| 2021-12-31 | -5.96% |
| 2021-09-30 | -8.25% |
| 2021-03-31 | -1.98% |
| 2020-12-31 | -2.16% |
